In 2024, Modern Retina covered news from around the globe on clinical trials, technology in retina, trending topics in ...

Panelists discuss how the chronic nature of retinal diseases requires consistent VEGF suppression through regular anti-VEGF injections, but this treatment burden leads to challenges including patient ...

Panelists discuss how the port delivery system (PDS) is a permanent, refillable ocular implant that continuously releases ranibizumab into the vitreous, with the Archway trial demonstrating ...

Video content above is prompted by the following: Could you briefly provide an overview of the new treatments available for retinal vascular diseases?

Finnish researchers, Hanna Heloterä, Anna-Mari Viita, and Juha Laine, reported the results of a study in which they gained a better perspective on registry data and the changing workload in ...

Did you miss any of our print issues this year? Don’t worry, they are still available online. In an increasingly digital world, where news moves swiftly and time is crunched, digital reading has ...

A single lot (Lot 10101) of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, is being voluntarily recalled by Alcon Laboratories due to the detection of fungal material in a ...

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery. A recent ...

The conference will be held January 13-16, 2025 in San Francisco, CA. Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development ...

The PFS is approved for treatment of neovascular age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion.

QUASAR is a global, double-masked, active-controlled phase 3 trial evaluating the efficacy and safety of EYLEA HD, compared to EYLEA, in patients with RVO, including those with central, branch and ...